Emerging data suggest that potent AR inhibition with enzalutamide leads to a massive up-regulation of GR expression, which then permits the re-expression of about 50% of AR-responsive genes, in turn promoting tumor progression (Arora et al., 2013; Isikbay et al., 2014). The gene discussed is AR; the disease is neoplasm.